Patents by Inventor Ilka Mathar
Ilka Mathar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240109864Abstract: The invention relates to substituted pyrazolo piperidine carboxylic acids, their salts and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular cardiovascular and cardiac diseases, preferably heart failure with reduced and preserved ejection fraction (HFrEF, HFmrEF and HFpEF), hypertension (HTN), peripheral arterial diseases (PAD, PAOD), cardio-renal and kidney diseases, preferably chronic and diabetic kidney disease (CKD and DKD), cardiopulmonary and lung diseases, preferable pulmonary hypertension (PH), and other diseases, preferably neurodegenerative diseases and different forms of dementias, fibrotic diseases, systemic sclerosis (SSc), sickle cell disease (SCD), wound healing disorders such as diabetic foot ulcer (DFU).Type: ApplicationFiled: December 9, 2021Publication date: April 4, 2024Inventors: Alexandros VAKALOPOULOS, Marie-Pierre COLLIN-KRÖPELIN, Nuria ORTEGA HERNANDEZ, Andre DIESKAU, Melissa BOULTADAKIS-ARAPINIS, Lisa CANDISH, Timo STELLFELD, Ilka MATHAR, Lucas Hudson HOFMEISTER, Peter SANDNER, Frank WUNDER, Lisa DIETZ, Robert Alan WEBSTER, Carsten SCHMECK
-
Publication number: 20240101528Abstract: The invention relates to substituted pyrazolo piperidine carboxylic acids, their salts and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular cardiovascular and cardiac diseases, preferably heart failure with reduced and preserved ejection fraction (HFrEF, HFmrEF and HFpEF), hypertension (HTN), peripheral arterial diseases (PAD, PAOD), cardio-renal and kidney diseases, preferably chronic and diabetic kidney disease (CKD and DKD), cardiopulmonary and lung diseases, preferable pulmonary hypertension (PH), and other diseases, preferably neurodegenerative diseases and different forms of dementias, fibrotic diseases, systemic sclerosis (SSc), sickle cell disease (SCD), wound healing disorders such as diabetic foot ulcer (DFU).Type: ApplicationFiled: December 9, 2021Publication date: March 28, 2024Inventors: Alexandros VAKALOPOULOS, Marie-Pierre COLLIN-KRÖPELIN, Nuria ORTEGA HERNANDEZ, Andre DIESKAU, Melissa BOULTADAKIS-ARAPINIS, Lisa CANDISH, Timo STELLFELD, Ilka MATHAR, Lucas Hudson HOFMEISTER, Peter SANDNER, Frank WUNDER, Lisa DIETZ, Robert Alan WEBSTER, Carsten SCHMECK
-
Publication number: 20240051935Abstract: The invention relates to substituted pyrazolo piperidine carboxylic acids, their salts and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular cardiovascular and cardiac diseases, preferably heart failure with reduced and preserved ejection fraction (HFrEF, HFmrEF and HFpEF), hypertension (HTN), peripheral arterial diseases (PAD, PAOD), cardio-renal and kidney diseases, preferably chronic and diabetic kidney disease (CKD and DKD), cardiopulmonary and lung diseases, preferable pulmonary hypertension (PH), and other diseases, preferably neurodegenerative diseases and different forms of dementias, fibrotic diseases, systemic sclerosis (SSc), sickle cell disease (SCD), wound healing disorders such as diabetic foot ulcer (DFU).Type: ApplicationFiled: December 9, 2021Publication date: February 15, 2024Inventors: Alexandros VAKALOPOULOS, Marie-Pierre COLLIN-KRÖPELIN, Nuria ORTEGA HERNANDEZ, Andre DIESKAU, Melissa BOULTADAKIS-ARAPINIS, Lisa CANDISH, Timo STELLFELD, Ilka MATHAR, Lucas Hudson HOFMEISTER, Peter SANDNER, Frank WUNDER, Lisa DIETZ, Robert Alan WEBSTER, Carsten SCHMECK, Thomas MONDRITZKI
-
Publication number: 20230265072Abstract: The invention relates to substituted pyrazolo piperidine carboxylic acids, their salts and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular cardiovascular and cardiac diseases, preferably heart failure with reduced and preserved ejection fraction (HFrEF, HFmrEF and HFpEF), hypertension (HTN), peripheral arterial diseases (PAD, PAOD), cardio-renal and kidney diseases, preferably chronic and diabetic kidney disease (CKD and DKD), cardiopulmonary and lung diseases, preferable pulmonary hypertension (PH), and other diseases, preferably neurodegenerative diseases and different forms of dementias, fibrotic diseases, systemic sclerosis (SSc), sickle cell disease (SCD), wound healing disorders such as diabetic foot ulcer (DFU).Type: ApplicationFiled: April 13, 2023Publication date: August 24, 2023Inventors: Alexandros VAKALOPOULOS, Marie-Pierre COLLIN-KRÖPELIN, Nuria ORTEGA HERNANDEZ, Andre DIESKAU, Melissa BOULTADAKIS-ARAPINIS, Lisa CANDISH, Timo STELLFELD, Ilka MATHAR, Lucas Hudson HOFMEISTER, Peter SANDNER, Frank WUNDER, Lisa DIETZ, Robert Alan WEBSTER, Carsten SCHMECK, Thomas MONDRITZKI
-
Publication number: 20230027985Abstract: The application relates to substituted hydantoinamides of formula (I) as ADAMTS7 antagonists, to processes for their preparation, their use alone or in combination for the treatment or prophylaxis of diseases, in particular of cardiovascular diseases, including atherosclerosis, coronary artery disease (CAD), peripheral vascular disease (PAD), arterial occlusive disease or restenosis after angioplasty. R1 is hydrogen, alkyl, cycloalkyl, heterocycloalkyl, 5- to 6-membered heteroaryl or phenyl; R2 is hydrogen or alkyl; A is 5-membered heteroaryl; Z is 6- to 10-membered aryl or 5- to 10-membered heteroaryl; all groups being optionally substituted.Type: ApplicationFiled: November 12, 2020Publication date: January 26, 2023Applicants: Bayer Aktiengesellschaft, The Broad Institute, Inc.Inventors: Daniel MEIBOM, Yolanda CANCHO GRANDE, Pierre WASNAIRE, Sarah Anna Liesa JOHANNES, Niels LINDNER, Kristin BEYER, Till FREUDENBERGER, Damian BROCKSCHNIEDER, Ilka MATHAR, Jürgen KLAR, Dmitry ZUBOV, Dzianis MENSHYKAU, Tanja KRAINZ, Eric STEFAN, Bryan MACDONALD, Yi XING, Nadine ELOWE, Guzman SANCHEZ
-
Patent number: 11439628Abstract: The present invention relates to non-steriodal mineralocorticoid receptor (MR) and the pharmacology of mineralocorticoid receptor antagonists (MR Antagonists, MRAs). In particular, the invention relates to the use of MRAs alone and in combination preferably in combination with sGC stimulators and/or sGC activators for preparation of medicaments for the prevention and/or treatment of muscular or neuromuscular diseases, especially for the treatment of Duchenne Muscular Dystrophy (DMD).Type: GrantFiled: May 10, 2019Date of Patent: September 13, 2022Assignee: BAYER AKTIENGESELLSCHAFTInventors: Peter Sandner, Peter Kolkhof, Ilka Mathar, Stefanie Breitenstein
-
Publication number: 20220274958Abstract: The invention relates to substituted pyrazolo piperidine carboxylic acids, their salts and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular cardiovascular and cardiac diseases, preferably heart failure with reduced and preserved ejection fraction (HFrEF, HFmrEF and HFpEF), hypertension (HTN), peripheral arterial diseases (PAD, PAOD), cardio-renal and kidney diseases, preferably chronic and diabetic kidney disease (CKD and DKD), cardiopulmonary and lung diseases, preferable pulmonary hypertension (PH), and other diseases, preferably neurodegenerative diseases and different forms of dementias, fibrotic diseases, systemic sclerosis (SSc), sickle cell disease (SCD), wound healing disorders such as diabetic foot ulcer (DFU).Type: ApplicationFiled: February 8, 2022Publication date: September 1, 2022Inventors: Alexandros VAKALOPOULOS, Marie-Pierre COLLIN-KRÖPELIN, Nuria ORTEGA HERNANDEZ, Andre DIESKAU, Melissa BOULTADAKIS-ARAPINIS, Lisa CANDISH, Timo STELLFELD, Ilka MATHAR, Lucas Hudson HOFMEISTER, Peter SANDNER, Frank WUNDER, Lisa DIETZ, Robert Alan WEBSTER, Carsten SCHMECK, Thomas MONDRITZKI
-
Publication number: 20210139555Abstract: The present invention relates to an antibody or a fragment thereof comprising at least one heterologous amino acid sequence incorporated within at least one CDR region of said antibody or fragment thereof, wherein said at least one heterologous amino acid sequence comprises an N-terminal linker sequence (Nils), an Atrial Natriuretic Peptide (ANP) and a C-terminal linker sequence (Ctls). Optionally, at least a portion of said at least one CDR region is replaced by said at least one heterologous amino acid sequence incorporated therein. The present invention further relates to such antibody or fragment thereof for use in a method for treatment, a composition comprising such antibody or fragment thereof, a nucleic acid or a mixture of nucleic acids encoding such antibody or fragment thereof, a host cell comprising such nucleic acid or such mixture of nucleic acids and to a process for producing such antibody or fragment thereof.Type: ApplicationFiled: April 10, 2019Publication date: May 13, 2021Applicant: Bayer AktiengesellschaftInventors: Anke MAYER-BARTSCHMID, Damian BROCKSCHNIEDER, Marcel GEERTZ, Simone GREVEN, Lucas Hudson HOFMEISTER, Hannah JÖRISSEN, Christoph MAHLERT, Tobias MARQUARDT, Ilka MATHAR, Thomas MONDRITZKI, Claudia NOACK, Jan TEBBE, Stuart WALSH, Ernst WEBER, Andreas WILMEN, Frank WUNDER
-
Publication number: 20210121447Abstract: The present invention relates to non-steriodal mineralocorticoid receptor (MR) and the pharmacology of mineralocorticoid receptor antagonists (MR Antagonists, MRAs). In particular, the invention relates to the use of MRAs alone and in combination preferably in combination with sGC stimulators and/or sGC activators for preparation of medicaments for the prevention and/or treatment of muscular or neuromuscular diseases, especially for the treatment of Duchenne Muscular Dystrophy (DMD).Type: ApplicationFiled: May 10, 2019Publication date: April 29, 2021Applicant: Bayer AktiengesellschaftInventors: Peter Sandner, Peter Kolkhof, Ilka Mathar, Stefanie Breitenstein